from the rapidly evolving industry of oncology exploration, accurate and efficient mutation screening is critical for developing focused therapies. The KRAS Services Platform performs a pivotal function On this landscape by presenting extensive methods for KRAS mutation profiling and Investigation. KRAS mutations, located in around 95% of RAS-conne